Hsp90 inhibitors with modified toxicity
The invention provides 19-substituted geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer and other proliferative tissue disorders.
1. A compound having the chemical structure:
or a pharmaceutically-acceptable salt thereof;
wherein:
R 3 is NHCH 2 CH═CH 2 , NHCH 2 CH 2 N(CH 3 ) 2 , NHCH 2 CH 2 NC 4 H 8 , alkoxy, azetidinyl, furfuryl, morpholinyl, piperazinyl, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofurfuryl, 2-methyl-1-aziridinyl, (dimethylamino)methyl-1-aziridinyl, 3-(dimethylamino)-1-azetidinyl, 3-hydroxy-1-pyrrolidinyl, 3,4-dihydroxy-1-pyrrolidinyl, or NR 8 R 9 , OR 8 , SR 8 , wherein R 8 and R 9 are independently H, C 1-10 alkyl, alkenyl, alkynyl, alkoxy, alkylhalide, alkyldihalide, amine, cycloalkyl, carboxyalkyl, (acetylamino)alkyl, (dimethylamino)alkyl, 1-(methoxymethyl)alkyl, 2-(1,3-dioxolan-2-yl)alkyl, 4,4-dimethoxybutyl, [[(1,1-dimethylethoxy)carbonyl]amino]alkyl, [[(1,1-dimethylethoxy)carbonyl]alkylamino]alkyl, 1-(hydroxymethyl)alkyl, 1-(hydroxymethyl)-2-methylalkyl, 2-(hydroxymethyl)cycloalkyl, (diethylamino)alkyl, 2-(dimethylamino)-1-methylethyl, (ethylmethylamino)alkyl, [(2-fluoroethyl)methylamino]alkyl, [(2,2-difluoroethyl)methylamino]alkyl, [bis(2-hydroxyethyl)amino]alkyl, (dimethyloxidoamino)alkyl, (trimethylammonio)alkyl, (1-aziridinyl)alkyl, (1-aziridinylmethyl)alkyl, (1-azetidinyl)alkyl, (2-deoxy-D-glucos-2-yl), (6-deoxy-D-glucos-6-yl), (1H-imidazol-4-yl)alkyl, (1-methyl-1H-imidazol-4-yl)alkyl, (1-methyl-1H-imidazol-5-yl)alkyl, (4-morpholinyl)alkyl, (4-pyridinyl)alkyl, (1-piperidinyl)alkyl, (1-piperazinyl)alkyl, (1-pyrrolidinyl)alkyl, (1-ethyl-2-pyrrolidinyl)methyl, or 2-(N-methyl-pyrrolidin-2-yl)ethyl;
R 4 and R 5 are independently H, C 1-6 alkyl, C 3-8 cycloalkyl, C(═O)C 1-10 alkyl, C(═O)(CH 2 ) n -aryl, C(═O)(CH 2 ) n -cycloalkyl, alkoxy, alkylthiol, glycoside, glucuronide or sulfate, wherein n=1-10;
R 6 is O, OC(═O)NH 2 , OC(═O)C 1-10 alkyl, OSO 2 OH, OC(═O)OSO 2 OH and OC(═O)NR 10 R 11 wherein R 10 and R 11 are independently H and C 1-10 alkyl; and,
R 7 is OH, NH 2 , CN, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, or alkylhalide.
2. The compound of claim 1 , wherein:
R 4 and R 5 are H,
R 6 is OC(═O)NH 2 , and,
R 7 is CH 3 , or CF 3 .
3. A compound having the chemical structure:
or a pharmaceutically-acceptable salt thereof;
wherein:
R 1 and R 2 are independently H, C 1-6 alkyl, C 3-8 cycloalkyl, C(═O)C 1-10 alkyl, C(═O)(CH 2 ) n -cycloalkyl, C(═O)(CH 2 ) n -aryl, wherein n=1-10, alkoxy, alkylthiol, glycoside, glucuronide or sulfate, C(═O)CH(X)NH 2 , and C(═O)CH(X)OH, wherein X=an amino acid side chain;
R 3 is NHCH 2 CH═CH 2 , NHCH 2 CH 2 N(CH 3 ) 2 , NHCH 2 CH 2 NC 4 H 8 , alkoxy, azetidinyl, furfuryl, morpholinyl, piperazinyl, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofurfuryl, 2-methyl-1-aziridinyl, (dimethylamino)methyl-1-aziridinyl, 3-(dimethylamino)-1-azetidinyl, 3-hydroxy-1-pyrrolidinyl, 3,4-dihydroxy-1-pyrrolidinyl, or NR 8 R 9 , OR 8 , SR 8 , wherein R 8 and R 9 are independently H, C 1-10 alkyl, alkenyl, alkynyl, alkoxy, alkylhalide, alkyldihalide, amine, cycloalkyl, carboxyalkyl, (acetylamino)alkyl, (dimethylamino)alkyl, 1-(methoxymethyl)alkyl, 2-(1,3-dioxolan-2-yl)alkyl, 4,4-dimethoxybutyl, [[(1,1-dimethylethoxy)carbonyl]amino]alkyl, [[(1,1-dimethylethoxy)carbonyl]alkylamino]alkyl, 1-(hydroxymethyl)alkyl, 1-(hydroxymethyl)-2-methylalkyl, 2-(hydroxymethyl)cycloalkyl, (diethylamino)alkyl, 2-(dimethylamino)-1-methylethyl, (ethylmethylamino)alkyl, [(2-fluoroethyl)methylamino]alkyl, [(2,2-difluoroethyl)methylamino]alkyl, [bis(2-hydroxyethyl)amino]alkyl, (dimethyloxidoamino)alkyl, (trimethylammonio)alkyl, (1-aziridinyl)alkyl, (1-aziridinylmethyl)alkyl, (1-azetidinyl)alkyl, (2-deoxy-D-glucos-2-yl), (6-deoxy-D-glucos-6-yl), (1H-imidazol-4-yl)alkyl, (1-methyl-1H-imidazol-4-yl)alkyl, (1-methyl-1H-imidazol-5-yl)alkyl, (4-morpholinyl)alkyl, (4-pyridinyl)alkyl, (1-piperidinyl)alkyl, (1-piperazinyl)alkyl, (1-pyrrolidinyl)alkyl, (1-ethyl-2-pyrrolidinyl)methyl, or 2-(N-methyl-pyrrolidin-2-yl)ethyl;
R 4 and R 5 are independently H, C 1-6 alkyl, C 3-8 cycloalkyl, C(═O)C 1-10 alkyl, C(═O)(CH 2 ) n -aryl, C(═O)(CH 2 ) n -cycloalkyl, alkoxy, alkylthiol, glycoside, glucuronide or sulfate, wherein n=1-10;
R 6 is O, OC(═O)NH 2 , OC(═O)C 1-10 alkyl, OSO 2 OH, OC(═O)OSO 2 OH and OC(═O)NR 10 R 11 wherein R 10 and R 11 are independently H and C 1-10 alkyl; and,
R 7 is OH, NH 2 , CN, C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, or alkylhalide.
4. The compound of claim 3 , wherein:
R 4 and R 5 are H,
R 6 is OC(═O)NH 2 , and,
R 7 is CH 3 , or CF 3 .
5. A method of treating cancer in a mammal comprising administering a therapeutically-effective amount of a compound of claim 1 to the mammal.
6. The method of claim 5 , wherein the compound is administered to the mammal in conjunction with an anti-cancer compound selected from the group consisting of a tyrosine kinase inhibitor, paclitaxel and doxorubicin.
7. The method of claim 5 , wherein the compound is administered to the mammal in conjunction with medically supervised radiation therapy.
8. A pharmaceutical composition comprising at least one of the compounds of claim 1 and a metal chelating agent.
9. The pharmaceutical composition of claim 8 wherein the metal chelating agent is a copper chelating agent.